靶向治疗在慢性乙型肝炎病毒感染中的研究进展
Advancements in targeted therapy for chronic hepatitis B virus infection
王聃 1张乘龙 2唐静 1邓琴 1杨磊 3孙强 4王艳1
作者信息
- 1. 资阳市第一人民医院感染科,四川资阳 641300
- 2. 遂宁市中心医院急诊科,四川遂宁 629000
- 3. 简阳市人民医院药学部,四川简阳 641400
- 4. 四川省人民医院药学部,四川成都 610000
- 折叠
摘要
目前临床治疗慢性乙型肝炎病毒(HBV)感染已取得一定进展,但现有的一线药物尚不能完全清除HBV共价闭合环状DNA从而彻底清除HBV.靶向治疗能特异性地结合靶点部位,从而阻断病毒入侵、病毒转录和蛋白翻译等,实现精准治疗.本文整理总结HBV生命周期不同阶段的靶点,从靶向病毒进入、靶向共价闭合环状DNA、靶向核心蛋白、靶向乙型肝炎表面抗原释放、靶向病毒转录等角度进行综述,以期为抗HBV感染的药物研发提供思路.
Abstract
Although some progress had been made in the treatment of chronic hepatitis B virus(HBV)infection,current first-line drugs failed to completely eliminate the covalently closed circular DNA(cccDNA)of HBV so as to completely eliminate HBV.Targeted therapy can specifically bind to the target sites,thereby blocking virus invasion,virus transcription,and protein translation,achieving precise treatment.Therefore,this article summarized and reviewed the targets at different stages of the HBV life cycle from the perspectives of targeting virus entry,targeting cccDNA,targeting core protein,targeting hepatitis B surface antigen(HBsAg)release,and targeting viral transcription,with a view to providing ideas for drug development against HBV infection.
关键词
乙型肝炎病毒/分子靶向治疗/慢性乙型肝炎/药物研发Key words
hepatitis B virus/molecular targeted therapy/chronic hepatitis B/drug development引用本文复制引用
基金项目
四川省科技厅重点研发项目(2023YFS0110)
出版年
2024
NETL
NSTL
万方数据